Understanding the Class Action Lawsuit Against Applied Therapeutics
Levi & Korsinsky, LLP is informing the investors of Applied Therapeutics, Inc. (NASDAQ: APLT) about a class action securities lawsuit that may significantly impact those who have invested in this company. As Applied Therapeutics faces serious allegations related to securities fraud, this lawsuit could be a crucial moment for numerous investors seeking justice for their losses.
Details of the Class Action Suit
This lawsuit aims to recover losses for investors who were adversely affected by alleged securities fraud activities that occurred from early January to early December. In light of recent developments within the company, it is imperative to understand the factors contributing to this lawsuit and the potential impacts on shareholders.
Identifying the Class
The class encompasses all stockholders of Applied Therapeutics during the specified timeframe when the alleged misconduct occurred. The suit is particularly relevant for those who held shares between January 3, 2024, and December 2, 2024, as it appears that numerous investors suffered substantial financial losses due to these allegations.
The Impact of Recent Developments
On November 27, 2024, Applied Therapeutics announced the receipt of a Complete Response Letter (CRL) from the FDA regarding their New Drug Application for the lead drug candidate, govorestat. This event triggered a significant decline in the company's stock price, raising questions and concerns among investors.
Stock Price Fluctuations
The aftermath of the FDA's refusal to approve the NDA highlighted critical deficiencies in the clinical application. Following this disclosure, the stock price plummeted drastically—from $10.21 per share on November 26, 2024, to $8.57 the next day and eventually dropping to a low of $1.75 by December 2, 2024. This staggering decline certainly caught the attention of investors, as the stock lost more than 80% of its value within a week, leading to heightened scrutiny of the company's actions.
Next Steps for Investors
For those affected, it is crucial to act swiftly. Investors who suffered losses during the relevant period need to be aware that they have until February 18, 2025, to petition the court for the designation of lead plaintiff status. However, it's essential to note that participating in the lawsuit does not require one to be a lead plaintiff to partake in any recovery.
No Financial Burden
Participating in this class action lawsuit comes without any financial risk. It is significant for investors to understand that they may qualify for compensation without any out-of-pocket costs. Levi & Korsinsky has emphasized that there is no cost or obligation to partake in the process, making it accessible for all affected investors.
Why Choose Levi & Korsinsky
Levi & Korsinsky has established a strong reputation over the past two decades in securing favorable outcomes for investors. Their portfolio showcases hundreds of millions recovered on behalf of shareholders, demonstrating their effectiveness in navigating complex securities litigation.
Proven Track Record
With a dedicated team of over 70 professionals, including experienced attorneys, Levi & Korsinsky's focus on client satisfaction and successful outcomes are evident. They have been recognized in the industry, consistently ranking among the top litigation firms for securities class actions across the nation.
Contact Information for Assistance
If you have experienced a loss in shares of Applied Therapeutics and wish to pursue this matter further, you may contact Levi & Korsinsky directly to discuss your options. They are prepared to assist investors in understanding their rights and potential next steps.
Frequently Asked Questions
What is the main purpose of the class action lawsuit?
The primary goal is to recover losses for investors affected by alleged securities fraud involving Applied Therapeutics.
How can I participate in the lawsuit?
Investors can enroll by expressing their interest before the deadline of February 18, 2025, without needing to be a lead plaintiff.
What were the reasons behind the stock price drop?
The stock price fell dramatically due to an unfavorable FDA response regarding the company’s primary drug candidate.
Are there any costs involved in joining the lawsuit?
No, there are no costs or obligations for class members to participate.
Why is Levi & Korsinsky a reliable choice for investor representation?
They have a proven track record, extensive experience in securities litigation, and a commitment to client success.
